Walvax BioTech (300142) - Total Liabilities
Based on the latest financial reports, Walvax BioTech (300142) has total liabilities worth CN¥3.17 Billion CNY (≈ $463.69 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 300142 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Walvax BioTech - Total Liabilities Trend (2007–2025)
This chart illustrates how Walvax BioTech's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 300142 total assets.
Walvax BioTech Competitors by Total Liabilities
The table below lists competitors of Walvax BioTech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Huada Automotive Tech Corp Ltd
SHG:603358
|
China | CN¥3.90 Billion |
|
Maximus Inc
NYSE:MMS
|
USA | $2.63 Billion |
|
Mr D I Y Group M Bhd
KLSE:5296
|
Malaysia | RM2.41 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥3.55 Billion |
|
FS KKR Capital Corp
NYSE:FSK
|
USA | $7.55 Billion |
|
PENNON GROUP PLC UNS.ADR2
F:3PN0
|
Germany | €6.02 Billion |
|
Provident Financial Services Inc
NYSE:PFS
|
USA | $22.76 Billion |
|
XJ Electric Co Ltd
SHE:000400
|
China | CN¥12.28 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Walvax BioTech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Walvax BioTech to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Walvax BioTech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Walvax BioTech (2007–2025)
The table below shows the annual total liabilities of Walvax BioTech from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.26 Billion ≈ $330.33 Million |
-29.82% |
| 2024-12-31 | CN¥3.22 Billion ≈ $470.67 Million |
-23.30% |
| 2023-12-31 | CN¥4.19 Billion ≈ $613.64 Million |
-3.51% |
| 2022-12-31 | CN¥4.35 Billion ≈ $635.99 Million |
+18.25% |
| 2021-12-31 | CN¥3.68 Billion ≈ $537.81 Million |
+104.18% |
| 2020-12-31 | CN¥1.80 Billion ≈ $263.40 Million |
+33.16% |
| 2019-12-31 | CN¥1.35 Billion ≈ $197.81 Million |
-31.83% |
| 2018-12-31 | CN¥1.98 Billion ≈ $290.15 Million |
-14.48% |
| 2017-12-31 | CN¥2.32 Billion ≈ $339.27 Million |
-17.21% |
| 2016-12-31 | CN¥2.80 Billion ≈ $409.78 Million |
-13.41% |
| 2015-12-31 | CN¥3.23 Billion ≈ $473.25 Million |
+17.36% |
| 2014-12-31 | CN¥2.76 Billion ≈ $403.25 Million |
-13.81% |
| 2013-12-31 | CN¥3.20 Billion ≈ $467.88 Million |
+149.66% |
| 2012-12-31 | CN¥1.28 Billion ≈ $187.41 Million |
+336.18% |
| 2011-12-31 | CN¥293.62 Million ≈ $42.97 Million |
-32.58% |
| 2010-12-31 | CN¥435.52 Million ≈ $63.73 Million |
+105.98% |
| 2009-12-31 | CN¥211.43 Million ≈ $30.94 Million |
+3.88% |
| 2008-12-31 | CN¥203.54 Million ≈ $29.78 Million |
+1.84% |
| 2007-12-31 | CN¥199.86 Million ≈ $29.25 Million |
-- |
About Walvax BioTech
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, grou… Read more